‘Postop is the new preop’ with the FDA approved light adjustable IOL
Click Here to Manage Email Alerts
WAILEA, Hawaii — With adjustable IOL technology, patients can have whatever refractive outcome they prefer and Vance M. Thompson, MD, FACS, proposes that power adjustment of the implant will be preferred to power adjustment of the cornea.
“I believe light adjustable technology could be the breakthrough we need in enhancement,” Thompson said at Hawaiian Eye 2018.
The Light Adjustable Lens from RxSight is the first IOL designed to be noninvasively adjusted after implantation using proprietary UV light, he said. The FDA approved the Light Adjustable Lens from RxSight in November 2017.
“We can learn lessons from LASIK, mainly how uncorrected distance vision drives patient satisfaction,” he said.
With LASIK, patient who achieve 20/20 levels and better provide for better patient satisfaction.
In an FDA investigation of the RxSight technology, 92% of patients achieved 20/25 or better. “We are getting LASIK-like outcomes,” he said.
“I feel that if a premium implant is put in we can learn lessons if we aren’t achieving 20/20. It’s hard to blame the implant for the lack of patient satisfaction,” Thompson continued.
Out of the implants used in the US, only 7.1% are premium, he said. Thompson’s practice has a rate of 40% premium IOL implantation use and many practices are doing even more.
He said this lens leads to a low stress cataract surgery, which is not dependent on prediction of surgically induced astigmatism, effective lens positioning, individual healing, surgical technique or sophisticated equipment.
The vision options are shown to the patient after surgery, which changes the preoperative and postoperative norms.
The postoperative process is interactive, he said. “The refraction is optimized with the patient after healing is complete and ocular media is clear.”
“Once a patient is happy with the visual result you lock it in and they get the curvature change for the rest of their life,” Thompson said.
He believes doctors and patients will be more attracted to this option and predicts an increase in premium technology with flexibility and adjustability. – by Abigail Sutton
Reference:
Thompson V. Light adjustable IOL. Presented at: Hawaiian Eye; Jan. 13-19, 2018; Wailea, Hawaii.
Disclosure: Thompson reports he is a consultant and conducts research for RxSight.